Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

biologische heilmittel heel gmbh dr. reckewegstrasse 2-4 76532 baden-baden (duitsland) - aconitum napellus d1 ; arnica montana d3 ; belladonna d1 ; bellis perennis ø ; calendula officinalis ø ; echinacea ø ; echinacea purpurea ø ; hamamelis virginiana ø ; hepar sulphur d6 ; hypericum perforatum d6 ; mercurius solubilis d6 ; symphytum officinale d4 - gel - , , , , , , , , , , , , , , , , , , , , , , - datum verstrekking handelsvergunning:11 april 2018

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

biologische heilmittel heel gmbh dr. reckewegstrasse 2-4 76532 baden-baden (duitsland) - belladonna d6 ; calcarea carbonica ostrearum d8 ; chamomilla d4 ; dulcamara d6 ; plantago major d4 ; pulsatilla pratensis d6 - drank - , , , , , , , , , , , , , , , , , , , ,

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

heel belgium n.v. booiebos 25 b-9031 drongen (belgiË) - aconitum napellus d6 ; agaricus muscarius d4 ; ammonium bromatum d4 ; atropinum sulfuricum d6 ; chamomilla d3 ; citrullus colocynthis d4 ; cuprum sulfuricum d6 ; gelsemium sempervirens d6 ; magnesium phosphoricum d6 ; passiflora incarnata d2 ; veratrum album d6 - tablet - lactose monohydrate ; magnesium stearate, , , , , , , - datum verstrekking handelsvergunning:27 juni 2017

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

heel belgium n.v. booiebos 25 b-9031 drongen (belgiË) - aconitum napellus d2 ; arnica montana d2 ; belladonna d2 ; bellis perennis d2 ; calendula officinalis d2 ; chamomilla d3 ; echinacea angustifolia d2 ; echinacea purpurea d2 ; hamamelis virginiana d1 ; hepar sulphur d6 ; hypericum perforatum d2 ; mercurius solubilis d6 ; millefolium d3 ; symphytum officinale d6 - oordruppels, oplossing - , , , , , , , , , , , , , , , , , , , , , , ,

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

heel belgium n.v. booiebos 25 b-9031 drongen (belgiË) - aconitum napellus d3 ; arnica montana d2 ; belladonna d4 ; bellis perennis d2 ; calendula officinalis d2 ; chamomilla d3 ; echinacea angustifolia d2 ; echinacea purpurea d2 ; hamamelis virginiana d2 ; hepar sulphur d8 ; hypericum perforatum d2 ; mercurius solubilis d8 ; millefolium d3 ; symphytum officinale d8 - druppels voor oraal gebruik, oplossing - , , , , , , , , , , , , , , , , , , , , ,

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dr. fisher farma b.v. - aconitum napellus d1; arnica montana d3; belladonna d1; bellis perennis ø; calendula officinalis ø; chamomilla ø; echinacea angustifolia ø; echinacea purpurea ø; hamamelis virginiana ø; hepar sulphur d6; hypericum perforatum d6; mercurius solubilis d6; millefolium ø; symphytum officinale d4; - crème - land van herkomst:duitsland

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

atropa bella-donna d2 ; calcarea carbonica ostrearum d8 ; matricaria recutita d1 ; plantago major d3 ; pulsatilla pratensis d2 - zetpil - hard fat

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

lannacher heilmittel gmbh - letrozol; - filmomhulde tablet - letrozole

Europese Unie - Nederlands - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; psoriasis; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; crohn disease; arthritis, juvenile rheumatoid - immunosuppressiva - rheumatoid arthritisyuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van gewrichtsschade, zoals gemeten door de x-ray en verbetering van fysiek functioneren, indien gegeven in combinatie met methotrexaat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisyuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab is niet onderzocht bij patiënten jonger dan 2 jaar. enthesitis-related arthritisyuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asyuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatic arthritisyuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van perifere gewrichtsschade, zoals gemeten door de x-ray bij patiënten met polyarticulaire symmetrische subtypen van de ziekte (zie hoofdstuk 5. 1) en aan het verbeteren van de fysieke functie. psoriasisyuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasisyuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 en 5. crohn’s diseaseyuflyma is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaseyuflyma is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitisyuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisyuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisyuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitisyuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - immunosuppressiva - de ziekte van crohn diseasestelara is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van crohn die een inadequate respons hadden, verloren reactie of intolerant waren voor zowel conventionele therapie of een tnfa-antagonist of medische contra-indicaties voor dergelijke therapieën. colitis colitisstelara is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve colitis ulcerosa die een ontoereikende respons, verloren reactie of intolerant waren voor zowel conventionele therapie of een biologische of medische contra-indicaties voor dergelijke therapieën. plaque psoriasisstelara is geïndiceerd voor de behandeling van matige tot ernstige plaque psoriasis bij volwassenen die niet reageren op, of een contra-indicatie of intolerantie voor andere systemische therapieën waaronder ciclosporine, methotrexaat en psoraleen ultraviolet-a. pediatrische plaque psoriasisstelara is geïndiceerd voor de behandeling van matige tot ernstige plaque psoriasis bij kinderen en adolescente patiënten vanaf de leeftijd van 6 jaar en ouder, die onvoldoende gecontroleerd worden door, of intolerantie voor andere systemische therapieën of phototherapies. psoriatica arthritisstelara, alleen of in combinatie met methotrexaat, is geïndiceerd voor de behandeling van actieve artritis psoriatica bij volwassen patiënten wanneer de respons op eerdere niet-biologische disease-modifying antirheumatic drug (dmard) therapie is dat er onvoldoende.